EB613 update reports larger bone-density gains in small osteoporosis subgroups

Entera Bio reported new exploratory findings for its investigational oral osteoporosis peptide EB613 on October 13, following presentations at the American Society for Bone and Mineral Research meeting in Boston. The update suggests that women starting with lower bone density may experience larger gains, a hypothesis relevant to selecting patients for further trials.

The findings come from a fresh analysis of an earlier study, rather than a newly completed trial. EB613 remains in development, and the update does not establish that it prevents fractures.

What the subgroup analysis found

According to Entera, six treated women with osteoporosis-range total-hip measurements had a mean placebo-adjusted bone mineral density gain of 4.23% at six months, compared with 1.02% among 15 women with less severe baseline measurements. The company also reported larger gains at the lumbar spine in the osteoporosis subgroup.

These comparisons were conducted after the original study and involved very small groups. They are useful for generating a research question: does baseline disease severity predict the response? They cannot reliably settle that question. A larger prospective study would need to test whether the apparent difference persists rather than reflecting chance or the characteristics of a few participants.

The randomized evidence behind the update

The underlying trial, published in the Journal of Bone and Mineral Research in 2024, randomized 161 postmenopausal women with low bone density or osteoporosis to several EB613 treatment groups or placebo. It was double-blind and lasted six months.

Its primary endpoint concerned the bone-formation marker P1NP at three months; bone-density changes were secondary endpoints. In the highest-dose group, the published analysis reported six-month improvements versus placebo of 2.7% at the lumbar spine, 1.8% at the total hip and 2.8% at the femoral neck.

Headache, nausea and dizziness were common adverse events. No serious adverse event was judged drug-related, although some participants discontinued medication because of adverse events. Short follow-up and small treatment groups limit conclusions about uncommon or longer-term harms.

The trial also excluded women with previous fractures and several important medical conditions. Its results therefore cannot automatically be extended to all patients encountered in osteoporosis practice, particularly those with more complex health needs.

Why the endpoint matters

Entera’s proposed Phase 3 study will compare EB613 with placebo in approximately 900 postmenopausal women, using total-hip bone-density change at 12 months as its primary efficacy measure. An extension would assess safety and durability through 24 months.

That design needs to be read alongside the precise scope of a separate regulatory development. On December 19, 2025, the FDA qualified percentage change in total-hip bone mineral density at 24 months, measured by DXA scanning, as a validated surrogate endpoint for certain osteoporosis drug trials.

A surrogate allows researchers to assess a measure supported as a predictor of clinical benefit instead of waiting to count the clinical events themselves. The FDA said this approach could make osteoporosis trials more efficient than traditional fracture-endpoint studies, which can require large populations and years of follow-up.

The agency’s general qualification specifies 24 months. It should not be treated as independent confirmation of every feature of Entera’s proposed 12-month protocol, or as approval of EB613.

For patients and clinicians, the development question is whether an oral bone-building peptide can deliver sufficiently durable benefits with acceptable safety. The current evidence supports further testing. It leaves fracture protection, longer-term tolerability and performance in a broader patient population unresolved.